Shares of Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) ended Wednesday session in green amid volatile trading. The shares closed up +0.052 points or 5.77% at $0.957 with 900,287.00 shares getting traded. Post opening the session at $0.91, the shares hit an intraday low of $0.89 and an intraday high of $0.96 and the price vacillated in this range throughout the day. The company has a market cap of $141.33 million and the numbers of outstanding shares have been calculated to be 155.75 million shares.
Navidea Biopharmaceuticals Inc (NAVB) on September 27, 2016 announced that its Board of Directors has appointed Michael M. Goldberg, M.D. as President and Chief Executive Officer effective September 22, 2016. The Board of Directors has also appointed Eric K. Rowinsky M.D., a Navidea board member since 2010, as Chairman of Navidea’s Board, a position previously held by Dr. Goldberg, who will remain a board member.
“We are delighted to announce the appointment of Michael as Navidea’s CEO,” said Dr. Rowinsky, Chairman of Navidea’s Compensation, Nominating and Governance committee and newly appointed Chairman. “Dr. Goldberg is a visionary leader with a deep knowledge and appreciation for the potential of Navidea’s macrophage targeting technology platform and its wide range of diagnostic and therapeutic applications. At this important transition point for the Company, we will benefit greatly from his expertise as we drive the development of our Manocept™ clinical immunodiagnostic and immunotherapeutic programs to deliver targeted products to improve patient outcomes.”
“I look forward to spearheading the growth of both Navidea and Macrophage Therapeutics as we execute our mission to not only diagnose but treat disease,” said Michael M. Goldberg, M.D. “The combination of exceptional technology, a strong leadership team as well as our expectation of improved financial stability will allow us to effectively execute on our strategy to more rapidly advance on numerous development programs with our ground-breaking proprietary technology for multiple high value indications.”
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) ended Wednesday session in red amid volatile trading. The shares closed down -0.28 points or -0.35% at $78.97 with 6.85 million shares getting traded. Post opening the session at $79.12, the shares hit an intraday low of $78.51 and an intraday high of $79.74 and the price vacillated in this range throughout the day. The company has a market cap of $102.44 billion and the numbers of outstanding shares have been calculated to be 1.32 billion shares.
Gilead Sciences, Inc. (GILD) on September 28, 2016 announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis (VL). As part of this collaboration, Gilead will donate 380,000 vials of AmBisome® (amphotericin B liposome for injection) to meet the needs of WHO to treat VL in key endemic countries, including Bangladesh, Ethiopia, India, Nepal, South Sudan and Sudan.
VL, also known as kala-azar, is the world’s second-deadliest parasitic infectious disease and affects up to 300,000 people annually in resource-limited countries.
“This new collaboration comes at the right time as we gear up to support endemic countries in the Eastern Africa sub-region and South-East Asia to eliminate visceral leishmaniasis as a public health problem by or before 2020,” said Dr. Ren Minghui, WHO Assistant Director-General for HIV/AIDS, Malaria and Neglected Tropical Diseases. “During the past five years, AmBisome, donated by Gilead, allowed many countries in the Region highly endemic for VL to implement WHO’s recommended first line treatment, benefitting thousands of people.”